BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance

W. T. Parker, A. L. Yeoman, B. A. Jamison, D. T. Yeung, H. S. Scott, T. P. Hughes, S. Branford

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)

Abstract

Background:BCR-ABL1 mutation analysis is recommended for chronic myeloid leukaemia patients. However, mutations may become undetectable after changing therapy, and it is unknown whether they have been eradicated.Methods:We examined longitudinal data of patients with imatinib-resistant mutations, which became undetectable by Sanger sequencing to determine whether mutations could reappear, and the related circumstances.Results:Identical imatinib- and nilotinib-resistant mutations reappeared following further therapy changes in five patients, and was associated with subsequent nilotinib resistance in four.Conclusion:The data suggest that some BCR-ABL1 mutations may persist at undetectable levels for many years after changing therapy, and can be reselected and confer resistance to subsequent inhibitors.

Original languageEnglish
Pages (from-to)1593-1598
Number of pages6
JournalBritish Journal of Cancer
Volume109
Issue number6
DOIs
Publication statusPublished or Issued - 17 Sep 2013

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this